Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM313 in Healthy Overweight and Obese Adults
NCT02708576Phase 1Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Feb 2016
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing NGM313 with Placebo (2 arms). Primary endpoint: Absolute change in weight at 84 days. Started Feb 2016; status: completed.
02
Drugs
NGM313
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02708576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02708576.